Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 174
Filter
2.
Indian J Pathol Microbiol ; 64(4): 806-809, 2021.
Article in English | MEDLINE | ID: mdl-34673610

ABSTRACT

Mesonephric adenocarcinoma (MNA) is a rare malignancy arising from the mesonephric remnant of the female reproductive tract, typically found in the cervix. MNA is uncommon in the uterine corpus, only 33 cases have been described in the literature. A 55-year-old postmenopausal woman presented with pink vaginal discharge and bilateral hip pain for 2 months, with the help of histopathologic observation and immunohistochemical staining, a diagnosis of "MNA" was made. The tumor invaded the whole layer of myometrium without endometrium involvement, mesonephric remnants and hyperplasia of the mesonephric duct were also found at the periphery of the neoplasm. After the operation, the patient was treated with 3 cycles of chemotherapy. The patient was followed for 6 months with disease. Further experience to diagnose and cure this rare tumor is warranted.


Subject(s)
Adenocarcinoma/pathology , Mesonephroma/pathology , Myometrium/pathology , Uterine Neoplasms/pathology , Wolffian Ducts/pathology , Adenocarcinoma/drug therapy , Adenocarcinoma/surgery , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor , Cervix Uteri/pathology , Female , Humans , Hysterectomy , Mesonephroma/drug therapy , Mesonephroma/surgery , Middle Aged , Salpingo-oophorectomy , Uterine Neoplasms/drug therapy , Uterine Neoplasms/surgery
3.
Rev. bras. ginecol. obstet ; 43(4): 329-333, Apr. 2021. tab, graf
Article in English | LILACS | ID: biblio-1280035

ABSTRACT

Abstract Introduction Malignant mesonephric tumors are uncommon in the female genital tract, and they are usually located where embryonic remnants of Wolffian ducts are detected, such as the uterine cervix. The information about these tumors, their treatment protocol, and prognosis are scarce. Case report A 60-year-old woman with postmenopausal vaginal bleeding was initially diagnosed with endometrial carcinoma. After suspicion co-testing, the patient underwent a loop electrosurgical excision of the cervix and was eventually diagnosed with mesonephric adenocarcinoma. She was subjected to a radical hysterectomy, which revealed International Federation of Gynecology and Obstetrics (FIGO) IB1 stage, and adjuvant radiotherapy. The follow-up showed no evidence of recurrence after 60 months. Conclusion We present the case of a woman with cervical mesonephric adenocarcinoma. When compared with the literature, this case had the longest clinical follow-up without evidence of recurrence, which reinforces the concept that these tumors are associated with a favorable prognosis if managed according to the guidelines defined for the treatment of patients with cervical adenocarcinomas. Though a rare entity, it should be kept in mind as a differential diagnosis for other cervical cancers.


Subject(s)
Humans , Female , Uterine Cervical Neoplasms/diagnosis , Mesonephroma/diagnosis , Uterine Cervical Neoplasms/surgery , Uterine Cervical Neoplasms/embryology , Uterine Cervical Neoplasms/pathology , Radiotherapy, Adjuvant , Diagnosis, Differential , Hysterectomy , Mesonephroma/surgery , Mesonephroma/embryology , Mesonephroma/pathology , Middle Aged , Neoplasm Invasiveness
4.
Rev Bras Ginecol Obstet ; 43(4): 329-333, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33784759

ABSTRACT

INTRODUCTION: Malignant mesonephric tumors are uncommon in the female genital tract, and they are usually located where embryonic remnants of Wolffian ducts are detected, such as the uterine cervix. The information about these tumors, their treatment protocol, and prognosis are scarce. CASE REPORT: A 60-year-old woman with postmenopausal vaginal bleeding was initially diagnosed with endometrial carcinoma. After suspicion co-testing, the patient underwent a loop electrosurgical excision of the cervix and was eventually diagnosed with mesonephric adenocarcinoma. She was subjected to a radical hysterectomy, which revealed International Federation of Gynecology and Obstetrics (FIGO) IB1 stage, and adjuvant radiotherapy. The follow-up showed no evidence of recurrence after 60 months. CONCLUSION: We present the case of a woman with cervical mesonephric adenocarcinoma. When compared with the literature, this case had the longest clinical follow-up without evidence of recurrence, which reinforces the concept that these tumors are associated with a favorable prognosis if managed according to the guidelines defined for the treatment of patients with cervical adenocarcinomas. Though a rare entity, it should be kept in mind as a differential diagnosis for other cervical cancers.


Subject(s)
Mesonephroma/diagnosis , Uterine Cervical Neoplasms/diagnosis , Diagnosis, Differential , Female , Humans , Hysterectomy , Mesonephroma/embryology , Mesonephroma/pathology , Mesonephroma/surgery , Middle Aged , Neoplasm Invasiveness , Radiotherapy, Adjuvant , Uterine Cervical Neoplasms/embryology , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgery
6.
Int J Gynecol Cancer ; 18(5): 1127-31, 2008.
Article in English | MEDLINE | ID: mdl-18028380

ABSTRACT

Mesonephric adenocarcinoma deriving from remnants of vaginal mesonephric ducts is one of the rarest tumors of the female genital tract with only three cases reported till date in international literature. Differential diagnosis from other aggressive tumors is complex and controversies exist in the literature regarding the biological behavior, prognosis, and optimal management strategies of these tumors. A 58-year-old woman presented with a large mass extending from the right adnexal region to the perineum and labia majora. CA125 was increased. A radical excision of the lesion with pelvic and para-aortic lymphadenectomy was performed. A well-capsulated mesonephric adenocarcinoma in a background of vaginal mesonephric remnants was diagnosed. Tumor cells showed immunoreactivity for pancytokeratin, cytokeratin (CK), CD 10, epithelial membrane antigen, vimentin, and calretinin; indeed they were negative for carcinoembryonic antigen, CK 20, estrogen receptor, and progesterone receptor. No evidence of lymph node involvement or metastatic disease was observed. The patient did not receive any adjuvant therapy and is alive and clinically free of disease at 1-year follow-up. In spite of the aggressive biological behavior attributed in literature to mesonephric carcinomas, which is probably due to the complex differential diagnosis with other müllerian tumors, the favorable course of our patient further supports the hypothesis that malignant mesonephric carcinomas may not behave aggressively and that radical surgery alone may be curative.


Subject(s)
Adenocarcinoma/pathology , Mesonephroma/pathology , Vaginal Neoplasms/pathology , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/surgery , Female , Follow-Up Studies , Humans , Immunohistochemistry , Mesonephroma/diagnostic imaging , Mesonephroma/surgery , Middle Aged , Time Factors , Tomography, X-Ray Computed , Vaginal Neoplasms/diagnostic imaging , Vaginal Neoplasms/surgery
8.
Gynecol Oncol ; 103(3): 1155-8, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17023031

ABSTRACT

BACKGROUND: Malignant mesonephric tumor arising in the uterine cervix is an exceedingly uncommon variant of cervical adenocarcinoma with only 30 well-documented cases in the literature. CASE: We present a case of a 54-year-old woman with postmenopausal vaginal bleeding who was found to have a stage IB mesonephric adenocarcinoma of the cervix. CONCLUSION: At present there is no consensus on a standardized treatment protocol for malignant mesonephric tumors of the cervix. The present case suggests that a favorable outcome may be achieved for patients with stage IB tumors with aggressive initial therapy.


Subject(s)
Mesonephroma/diagnosis , Uterine Cervical Neoplasms/diagnosis , Diagnosis, Differential , Female , Humans , Mesonephroma/pathology , Mesonephroma/surgery , Middle Aged , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgery
9.
Int J Gynecol Cancer ; 16(3): 1450-4, 2006.
Article in English | MEDLINE | ID: mdl-16803547

ABSTRACT

A second report of an intramural mesonephric adenocarcinoma of the uterus is presented. The histogenesis and clinicopathologic outcome of a surgically staged malignancy add to the insights and experience of this uncommon disorder.


Subject(s)
Adenocarcinoma/diagnosis , Mesonephroma/diagnosis , Uterine Neoplasms/diagnosis , Adenocarcinoma/surgery , Aged, 80 and over , Biomarkers, Tumor/metabolism , Calbindin 2 , Female , Humans , Immunohistochemistry/methods , Mesonephroma/surgery , Neoplasm Invasiveness/diagnosis , S100 Calcium Binding Protein G/metabolism , Uterine Neoplasms/surgery
10.
Ginekol Pol ; 73(4): 350-3, 2002 Apr.
Article in Polish | MEDLINE | ID: mdl-12152283

ABSTRACT

OBJECTIVE: Ovarian tumors during pregnancy are a rare event. More ovarian tumors are detected accidently during ultrasonography examination or caesarean section at term. STUDY DESIGN: Ovarian tumor was recognized at the 36 years old patient during 21 weeks of pregnancy and was observed and treated during caesarean section. RESULTS: During caesarean section the mesonephroid ovarian carcinoma at IA stage has been diagnosed and unilateral cystectomy after meticulous surgical exploration was done.


Subject(s)
Mesonephroma , Ovarian Neoplasms , Pregnancy Complications, Neoplastic , Adult , Cesarean Section , Female , Humans , Mesonephroma/diagnostic imaging , Mesonephroma/surgery , Obstetric Labor Complications/surgery , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/surgery , Pregnancy , Pregnancy Complications, Neoplastic/diagnostic imaging , Pregnancy Complications, Neoplastic/surgery , Pregnancy Outcome , Treatment Outcome , Ultrasonography
12.
Am J Surg Pathol ; 25(3): 379-87, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11224609

ABSTRACT

Mesonephric adenocarcinoma is a rare variant of cervical carcinoma with relatively few, well-documented cases reported. We describe the clinicopathologic and immunohistochemical features of 11 examples of this neoplasm, which occurred in women between the ages of 35 and 72 years (mean, 52 years). Most (64%) patients had abnormal vaginal bleeding. Eight tumors were stage IB, and one each was stage IIB and IVB; in one, the stage was unknown. Microscopically, the carcinomas showed various morphologies, most commonly a small tubular pattern or a ductal pattern resembling endometrioid adenocarcinoma; one tumor had an associated malignant spindle cell component. Ten neoplasms were adjacent to hyperplastic mesonephric remnants. Follow-up in 10 cases showed six patients to be alive without evidence of recurrence after a mean of 4.8 years. The patients with stage IIB and IVB disease had local recurrences after 2.2 and 0.7 years and died of progressive disease at 3.2 and 0.8 years, respectively. In a patient with stage IB disease, a mediastinal metastasis and a malignant pleural effusion developed 5.6 years after diagnosis, and the patient died of disease at 6.2 years. Another patient with stage IB disease and a positive vaginal cuff margin that recurred locally after 1.7 years received chemotherapy and was alive and clinically free of disease at 2.5 years. Mesonephric adenocarcinomas were immunoreactive for epithelial markers (AE1/3; CK1, CAM 5.2, cytokeratin 7, and epithelial membrane antigen) (100%), calretinin (88%), vimentin (70%), androgen receptor (33%), and inhibin (30%, focal staining). No immunostaining was detected with cytokeratin 20, estrogen receptor, progesterone receptor, and monoclonal carcinoembryonic antigen. This staining profile is similar to that of mesonephric remnants and may be useful in the distinction of mesonephric carcinoma from mullerian endometrioid adenocarcinoma, with which it may be confused.


Subject(s)
Mesonephroma/pathology , Uterine Cervical Neoplasms/pathology , Adult , Aged , Biomarkers, Tumor/analysis , Carcinoma, Endometrioid/diagnosis , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Immunoenzyme Techniques , Mesonephroma/chemistry , Mesonephroma/mortality , Mesonephroma/surgery , Middle Aged , Neoplasm Proteins/analysis , Neoplasm Staging , Survival Rate , Uterine Cervical Neoplasms/chemistry , Uterine Cervical Neoplasms/mortality , Uterine Cervical Neoplasms/surgery
14.
Pediatr Pathol Lab Med ; 15(5): 679-88, 1995.
Article in English | MEDLINE | ID: mdl-8597855

ABSTRACT

A large congenital mesoblastic nephroma (CMN) of combined classical and and cellular histological structure was removed from a 1-month-old female infant. The tumor extended extrarenally and may have been incompletely excised. Tumor tissue showed a mosaic hyperdiploidy with 54 chromosomes in the hyperdiploid line. No other antitumor therapy was given and there has been no recurrence after 4 years. Genomic imprinting normally prevents transcription of the maternal gene for insulin-like growth factor 2 (IGF2). Relaxation of IGF2 imprinting leading to abnormal transcription of the maternal gene is found in a majority of Wilms' tumors and in other malignant neoplasms. The biallelic transcription of IGF2 demonstrated in the CMN from this case is consistent with abnormal transcription of the maternal allele. Relaxation of imprinting of the maternal IGF2 gene or abnormal expression of the gene through other mechanisms may have a role in the genesis of CMN or the cellular subtype.


Subject(s)
Diploidy , Genomic Imprinting , Insulin-Like Growth Factor II/genetics , Kidney Neoplasms/genetics , Kidney Neoplasms/pathology , Mesonephroma/genetics , Mesonephroma/pathology , Female , Humans , Infant, Newborn , Karyotyping , Kidney Neoplasms/surgery , Mesonephroma/surgery , Prognosis
15.
Gynecol Oncol ; 50(2): 247-8, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8397155

ABSTRACT

A case of a 19-year-old female with 46 XY gonadal dysgenesis and five different histological subtypes of germ cell malignancies is described. Both adnexa were removed, preserving the uterus. Pathology revealed gonadoblastoma with dysgerminoma differentiation present in both gonads and in the left gonad mature teratoma, embryonal carcinoma, and endodermal sinus tumor were identified as well. She received no adjuvant treatment and has remained well 30 months after diagnosis.


Subject(s)
Genital Neoplasms, Female/complications , Gonadal Dysgenesis, 46,XY/complications , Neoplasms, Germ Cell and Embryonal/complications , Adnexa Uteri/pathology , Adnexa Uteri/surgery , Adult , Dysgerminoma/complications , Dysgerminoma/pathology , Dysgerminoma/surgery , Female , Genital Neoplasms, Female/pathology , Genital Neoplasms, Female/surgery , Gonadal Dysgenesis, 46,XY/pathology , Humans , Mesonephroma/complications , Mesonephroma/pathology , Mesonephroma/surgery , Neoplasms, Germ Cell and Embryonal/pathology , Neoplasms, Germ Cell and Embryonal/surgery , Teratoma/complications , Teratoma/pathology , Teratoma/surgery
16.
Int J Gynecol Pathol ; 12(3): 264-9, 1993 Jul.
Article in English | MEDLINE | ID: mdl-7688354

ABSTRACT

A case of cervical adenocarcinoma arising in diffuse mesonephric hyperplasia is presented. The hyperplastic and neoplastic tubules showed focal endocrine cell differentiation. Endocrine cells stained with the Grimelius technique, and were immunoreactive for chromogranin and serotonin. Antisera to additional specific hormones were negative. The natural history of this rare tumor is uncertain; the patient presented in this report is free of disease at 10-year follow-up.


Subject(s)
Mesonephroma/pathology , Uterine Cervical Neoplasms/pathology , Adult , Cell Differentiation , Cervix Uteri/pathology , Chromogranins/analysis , Female , Humans , Hysterectomy , Immunoenzyme Techniques , Keratins/analysis , Mesonephroma/surgery , Serotonin/analysis , Staining and Labeling , Uterine Cervical Neoplasms/surgery , Uterus/pathology , Vimentin/analysis
17.
Klin Padiatr ; 205(4): 225-30, 1993.
Article in German | MEDLINE | ID: mdl-8397320

ABSTRACT

The GPOH-MAHO trials designed in 3/82 and 7/88 for treatment of childhood testicular germ cell tumors registered 3/92 105 pts. In MAHO 82 study 57 pts. and in MAHO 88 study 48 pts. were treated. Histologically 60% of the tumors revealed yolk sac tumors (YST), 22% teratomas (TD) and 18% malignant teratomas (MTI, MTU, MTT). Beside unilateral orchiectomy, according to stage and histology a stratified chemotherapy was administered. Standard chemotherapy consisted of 4 courses VLB, BLM, DDP, after 2 courses standard chemotherapy if vital tumor was suspected: explorative laparatomy. According to laparatomy some patients received salvage chemotherapy of 3 courses VP 16, IFO and DDP. The following results were obtained: YST: 59 pts. with stage I. Of these 10 received adjuvant chemotherapy with VLB, BML, DDP. 49 pts. were followed according to wait and see policy and not treated by adjuvant chemotherapy; 8 pts. had a relapse. 5 were treated with standard chemotherapy and 1 pt. with salvage therapy. 1 pt. had stage II and another stage III. Both received standard chemotherapy. The survival of all 61 pts. is 100%. Median observation time is 4 years. TD: 25 pts. had stage I. No chemotherapy was given. The relapse free survival is 100%. Median observation time is 4 years. Malignant teratomas (MTI, MTU, MTT): 8 pts. had stage I. Of these 3 received adjuvant chemotherapy, 5 lymphadenectomy without chemotherapy. All patients survived without relapse. 8 pts. had stage II and received standard chemotherapy, of these 4 pts. had stage IIc and explorative laparotomy was done. According to the result 2 pts. received salvage therapy. All pts. survived relapse free.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms, Germ Cell and Embryonal/drug therapy , Testicular Neoplasms/drug therapy , Adolescent , Chemotherapy, Adjuvant , Child , Child, Preschool , Combined Modality Therapy , Follow-Up Studies , Humans , Lymph Node Excision , Lymphatic Metastasis , Male , Mesonephroma/drug therapy , Mesonephroma/mortality , Mesonephroma/pathology , Mesonephroma/surgery , Neoplasm Staging , Neoplasms, Germ Cell and Embryonal/mortality , Neoplasms, Germ Cell and Embryonal/pathology , Neoplasms, Germ Cell and Embryonal/surgery , Survival Rate , Teratoma/drug therapy , Teratoma/mortality , Teratoma/pathology , Teratoma/surgery , Testicular Neoplasms/mortality , Testicular Neoplasms/pathology , Testicular Neoplasms/surgery
18.
Acta Obstet Gynecol Scand ; 72(5): 391-5, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8392273

ABSTRACT

Serum concentration of PIIINP (aminoterminal propeptide of type III procollagen), an indicator of connective tissue metabolism, is often increased in advanced gynecological carcinoma and correlates with the tumor growth. Because the healing wound also affects collagen metabolism we measured the serum PIIINP concentration in 15 patients operated on for endometrial carcinoma and in 28 patients operated on for benign gynecological diseases. Serial serum samples were collected for 35-51 days after surgery. In endometrial carcinoma, serum PIIINP level was increased in 53% of the patients before the operation. Postoperatively, the mean PIIINP concentration increased further, remaining at a pathological level throughout the study and with a peak at one week after the operation. In relative terms an abdominal operation for benign disease increased the serum PIIINP concentration as much as in endometrial carcinoma, but the mean level remained within the reference interval. After vaginal operation the increase in PIIINP concentration was not significant. The initially increased PIIINP concentration in endometrial carcinoma is probably caused by the effects of the malignancy on collagen metabolism. Because the relative response of PIIINP to abdominal operation was similar in both groups, the PIIINP response to surgical trauma in patients with malignant disease seems to depend only on the extent of the operation. In this group the transient increase in serum PIIINP concentration does not prevent the use of PIIINP as a tumor marker, since the follow-up examinations for malignancy do not start earlier than two months after operation.


Subject(s)
Endometrial Neoplasms/blood , Endometrial Neoplasms/surgery , Genital Diseases, Female/blood , Genital Diseases, Female/surgery , Peptide Fragments/blood , Procollagen/blood , Adenocarcinoma/blood , Adenocarcinoma/surgery , Female , Follow-Up Studies , Humans , Mesonephroma/blood , Mesonephroma/surgery , Middle Aged , Postoperative Care , Preoperative Care , Sarcoma/blood , Sarcoma/surgery
19.
Chin Med J (Engl) ; 106(4): 303-6, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8325159

ABSTRACT

Conservative operation and postoperative chemotherapy were given to 15 patients with malignant germ cell tumors of the ovary with the preservation of fertility and ovarian functions. Four patients, one with endodermal sinus tumor and three immature teratoma, had full term deliveries after the operation. The possibility was discussed to preserve young women's fertility and ovarian function in treating their malignant germ cell tumors.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fertility , Mesonephroma/surgery , Ovarian Neoplasms/surgery , Teratoma/surgery , Adolescent , Adult , Chemotherapy, Adjuvant , Child , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Dactinomycin/administration & dosage , Female , Humans , Mesonephroma/drug therapy , Ovarian Neoplasms/drug therapy , Teratoma/drug therapy , Vincristine/administration & dosage
20.
Gynecol Oncol ; 48(3): 402-5, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8462907

ABSTRACT

Endodermal sinus tumor is a rare and highly malignant lesion. This report documents the clinical findings and magnetic resonance imaging (MRI) of an uncommon case of the endodermal sinus tumor arising in the vagina of a 6-month-old infant. MRI was extremely accurate in delineating the possible extent and location of the vaginal lesion. This is the first report to demonstrate MRI of vaginal endodermal sinus tumor.


Subject(s)
Magnetic Resonance Imaging , Mesonephroma/diagnosis , Vaginal Neoplasms/diagnosis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclophosphamide/therapeutic use , Dactinomycin/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Hysterectomy , Infant , Mesonephroma/drug therapy , Mesonephroma/pathology , Mesonephroma/surgery , Vagina/surgery , Vaginal Neoplasms/drug therapy , Vaginal Neoplasms/pathology , Vaginal Neoplasms/surgery , Vincristine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...